What is it about?
We describe the first immunoproteasome selective inhibitor targeting all three proteolytically active immunoproteasome subunits with respect to selectivity and biological activity. This study substantiates that the immunoproteasome is a promising drug target for the treatment of inflammatory diseases and that exclusive inhibition of LMP7 is not necessary for therapeutic effectiveness.
Featured Image
Read the Original
This page is a summary of: Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome, British Journal of Pharmacology, November 2017, Wiley,
DOI: 10.1111/bph.14069.
You can read the full text:
Contributors
Be the first to contribute to this page







